

Supplemental information

Prevention and therapy of SARS-CoV-2

and the B.1.351 variant in mice

David R. Martinez, Alexandra Schäfer, Sarah R. Leist, Dapeng Li, Kendra Gully, Boyd Yount, Joy Y. Feng, Elaine Bunyan, Danielle P. Porter, Tomas Cihlar, Stephanie A. Montgomery, Barton F. Haynes, Ralph S. Baric, Michel C. Nussenzweig, and Timothy P. Sheahan

Figure S1




Figure S1. The prophylactic efficacy of mAb monotherapy against SARS-CoV-2 in mice treated at 12 hours before infection.

(A) % starting weight in therapeutically treated mice with C144, C135, or an HIV mAb at 12 hours before infection.

(B) Lung viral titers in therapeutically treated mice at 12 hours before infection.

(C) Lung discoloration score in therapeutically treated mice at 12 hours before infection.

(D-E) Lung pathology in therapeutically treated mice at 12 hours before infection. P values are from a 2-way ANOVA after Sidak's multiple comparisons test. Related to Figure 3.

Figure S2




Figure S2. The therapeutic efficacy of mAb monotherapy against SARS-CoV-2 in mice treated at 12 hours post infection.

(A) % starting weight in therapeutically treated mice with C144, C135, or an HIV mAb at 12 hours post infection.

(B) Lung viral titers in therapeutically treated mice at 12 hours post infection.

(C) Lung discoloration score in therapeutically treated mice at 12 hours post infection.

(D-E) Lung pathology in therapeutically treated mice at 12 hours post infection. P values are from a 2-way ANOVA after Sidak's multiple comparisons test. Related to Figure 3.

Figure S3




Figure S3. The therapeutic efficacy of mAb monotherapy against SARS-CoV-2 in mice treated at 24 hours post infection.

(A) % starting weight in therapeutically treated mice with C144, C135, or an HIV mAb at 24 hours post infection.

(B) Lung viral titers in therapeutically treated mice at 24 hours post infection.

(C) Lung discoloration score in therapeutically treated mice at 24 hours post infection.

(D-E) Lung pathology in therapeutically treated mice at 24 hours post infection. P values are from a 2-way ANOVA after Sidak's multiple comparisons test. Related to Figure 3.

Figure S4




Figure S4. The therapeutic efficacy of mAb monotherapy against SARS-CoV-2 in mice treated at 48 hours post infection.

(A) % starting weight in therapeutically treated mice with C144, C135, or an HIV mAb at 48 hours post infection.

(B) Lung viral titers in therapeutically treated mice at 48 hours post infection.

(C) Lung discoloration score in therapeutically treated mice at 48 hours post infection.

(D-E) Lung pathology in therapeutically treated mice at 48 hours post infection. P values are from a 2-way ANOVA after Sidak's multiple comparisons test. Related to Figure 3.

